Biomedical Engineering Reference
In-Depth Information
had not been established. As a result, the tumor ECF disposition of topotecan
using microdialysis methodology was evaluated and the relationship between
topotecan tumor ECF exposure and antitumor response in mice bearing the
relatively resistant (NB1691) and sensitive (NB1643) human neuroblastoma
xenografts was evaluated (Zamboni et al., 1999).
The concentration versus time profiles of topotecan in plasma and tumor ECF
in NB1643 and NB1691 human tumor xenografts are presented in Fig. 21.4.
21.4 Topotecan lactone concentration versus time profiles inplasma and tumor
ECF in resistant and sensitive neuroblastoma tumor xenografts. Representative
topotecan plasma (A) and tumor extracellular fluid (ECF) (B) concentration±
time plots in mice bearing NB-1691 (, ----) and NB-1643 (l, ÐÐ).
Individual data points and best fit line of the data are shown. The topotecan
lactone tumor extracellular fluid AUC 0 to 5 hours for the representative NB-
1643 and NB-1691 tumor xenografts were 22.3 and 9.1ng/ml h, respectively.
Search WWH ::
Custom Search